KFDA not allows 3 COX-2 inhibitors to register.
Published: 2005-12-29 06:59:00
Updated: 2005-12-29 06:59:00
Amid the safety problem of Celebrex, a COX-2 inhibitor, the KFDA said on Dec. 26 that the clinical studies of Bextra 100mg and 200mg (baldecoxcib) and the health registation of Palecoxib (Dynastat inj.) should not be allowed due to the risk of cardiovascular problems.
The KFDA's measure seems...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
